Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$13.92
+9.6%		$9.97
$2.74
▼
$14.23
$3.89B1.323.98 million shs7.78 million shs
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$29.85
+1.2%		$28.80
$10.83
▼
$41.14
$3.29B-0.131.53 million shs976,943 shs
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
$14.00
$13.98
$0.78
▼
$25.00
$1.00B1.263.32 million shs5.45 million shs
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$36.72
-0.6%		$58.56
$36.07
▼
$72.66
$3.57B0.612.09 million shs2.52 million shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
+9.61%+9.95%+22.64%+77.51%+193.67%
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
+1.22%-7.84%-14.08%+66.33%+105.58%
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
0.00%0.00%0.00%0.00%+369.80%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-0.60%-5.82%-38.79%-39.17%-3.32%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$13.92
+9.6%		$9.97
$2.74
▼
$14.23
$3.89B1.323.98 million shs7.78 million shs
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$29.85
+1.2%		$28.80
$10.83
▼
$41.14
$3.29B-0.131.53 million shs976,943 shs
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
$14.00
$13.98
$0.78
▼
$25.00
$1.00B1.263.32 million shs5.45 million shs
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$36.72
-0.6%		$58.56
$36.07
▼
$72.66
$3.57B0.612.09 million shs2.52 million shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
+9.61%+9.95%+22.64%+77.51%+193.67%
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
+1.22%-7.84%-14.08%+66.33%+105.58%
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
0.00%0.00%0.00%0.00%+369.80%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-0.60%-5.82%-38.79%-39.17%-3.32%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
2.63
Moderate Buy$12.86-7.64% Downside
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
3.00
Buy$38.8630.17% Upside
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
1.89
Reduce$14.00N/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
2.94
Moderate Buy$70.2791.36% Upside

Current Analyst Ratings Breakdown

Latest VTYX, ABCL, XENE, and AMLX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/28/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$90.00
9/24/2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$13.00
9/18/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/18/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$69.00 ➝ $64.00
9/18/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$90.00 ➝ $46.00
9/18/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold$90.00 ➝ $46.00
9/18/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$81.00 ➝ $70.00
9/18/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$71.00 ➝ $55.00
9/18/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$97.00 ➝ $90.00
9/18/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$78.00 ➝ $60.00
8/27/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$55.00 ➝ $57.00
(Data available from 9/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$75.13M56.81N/AN/A$3.23 per share4.31
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$87.37M38.07N/AN/A$2.78 per share10.74
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
N/AN/AN/AN/A$3.59 per shareN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$7.50M473.30N/AN/A$7.53 per share4.88
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$146.41M-$0.54N/AN/AN/A-248.83%-17.49%-12.36%11/5/2026 (Estimated)
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$144.74M-$1.43N/AN/AN/AN/A-52.92%-48.53%11/5/2026 (Estimated)
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
-$135.12M-$1.50N/AN/AN/AN/A-48.11%-43.89%N/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$345.91M-$4.74N/AN/AN/AN/A-43.98%-41.72%11/2/2026 (Estimated)

Latest VTYX, ABCL, XENE, and AMLX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$0.3609-$0.39-$0.0291-$0.39N/AN/A
8/6/2026Q2 2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$1.16-$1.11+$0.05-$1.11$1.67 millionN/A
8/5/2026Q2 2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$0.1640-$0.18-$0.0160-$0.18$7.85 million$4.05 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/AN/AN/AN/AN/A
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/AN/AN/AN/AN/A
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
N/AN/AN/AN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/A
12.77
12.77
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/A
12.12
12.12
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
N/A
17.86
17.86
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/A
21.01
21.02

Institutional Ownership

CompanyInstitutional Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
61.42%
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
95.84%
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
97.88%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
95.45%

Insider Ownership

CompanyInsider Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
28.40%
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
10.90%
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
14.49%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
2.91%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
562306.61 million219.53 millionOptionable
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
136111.42 million99.28 millionOptionable
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
3071.76 million61.36 millionOptionable
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
37096.67 million93.85 millionOptionable

Recent News About These Companies

Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors
 |  newsfilecorp.comN
Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review
September 27 at 12:01 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/event-xenon-files-azetukalner-nda-as-it-pauses-psychiatry-trials-for-tolerability-review-2026-09-27/
Bank of America Corp DE Buys New Holdings in Xenon Pharmaceuticals Inc. $XENE
September 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-buys-new-holdings-in-xenon-pharmaceuticals-inc-xene-2026-09-24/
XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law
September 22, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260922922322/en/xene-investors-have-opportunity-to-join-xenon-pharmaceuticals-inc.-fraud-investigation-with-sbs-law/
Xenon Pharmaceuticals (XENE) Seeks Epilepsy Approval. Can its Drug Overcome a Depression Setback?
September 22, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/news/xenon-pharmaceuticals-xene-seeks-epilepsy-approval-can-its-drug-overcome-a-depression-setback-1840507/
Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE)
September 22, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/xenon-pharmaceuticals-investigation-notice-suewallst-notifies-investors-of-pending-investigation-into-xenon-pharmaceuticals-xene-302886738.html
Xenon Pharmaceuticals: Azetukalner Still Has Potential As An Epilepsy Candidate
September 22, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4948590-xenon-pharmaceuticals-azetukalner-still-has-potential-as-an-epilepsy-candidate
Wolf Popper LLP Announces Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
September 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/22/3366207/1453/en/wolf-popper-llp-announces-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors.html
Xenon stock lost 30%, but the FDA story is more complicated
September 21, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/xenon-stock-lost-30-but-the-fda-story-is-more-complicated/ar-AA2cHUcA
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
September 21, 2026  |  financialpost.comF
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
September 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/21/3365849/33485/en/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit.html
Xenon shares slide more than 30% as company pauses psychiatry trial enrollment
September 21, 2026  |  thepharmaletter.comT
Xenon Pharmaceuticals Stock Sinks 31% After Pausing Depression Study Enrollment
September 21, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/xenon-pharmaceuticals-stock-sinks-31-113727807.html
Xenon Pharmaceuticals (NASDAQ:XENE) Sees Unusually-High Trading Volume - Time to Buy?
September 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-xenon-pharmaceuticals-nasdaq-xene-sees-unusually-high-trading-volume-time-to-buy-2026-09-21/
Xenon Pharmaceuticals Inc (XENE)
September 20, 2026  |  za.investing.comhttps://za.investing.com/equities/xenon-pharmaceuticals-consensus-estimates
Robert W. Baird Issues Pessimistic Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price
September 20, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31034223
Needham & Company LLC Has Lowered Expectations for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price
September 20, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31034216
Royal Bank Of Canada Lowers Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $70.00
September 20, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31033910
Wedbush Lowers Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $55.00
September 20, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31033817
Goldman Sachs Sticks to Its Buy Rating for Xenon (XENE)
September 19, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/XENE-Q/pressreleases/4694474/goldman-sachs-sticks-to-its-buy-rating-for-xenon-xene/
Why Xenon Pharmaceuticals (XENE) Is Down 32.2% After Pausing Psychiatry Trials Despite Positive NDA Data
September 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/why-xenon-pharmaceuticals-xene-down-002009302.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

AbCellera Biologics stock logo

AbCellera Biologics NASDAQ:ABCL

$13.92 +1.22 (+9.61%)
Closing price 09/28/2026 04:00 PM Eastern
Extended Trading
$14.33 +0.41 (+2.95%)
As of 08:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Amylyx Pharmaceuticals stock logo

Amylyx Pharmaceuticals NASDAQ:AMLX

$29.85 +0.36 (+1.22%)
Closing price 09/28/2026 04:00 PM Eastern
Extended Trading
$29.97 +0.12 (+0.40%)
As of 08:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

Ventyx Biosciences stock logo

Ventyx Biosciences NASDAQ:VTYX

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

Xenon Pharmaceuticals stock logo

Xenon Pharmaceuticals NASDAQ:XENE

$36.72 -0.22 (-0.60%)
Closing price 09/28/2026 04:00 PM Eastern
Extended Trading
$36.64 -0.08 (-0.21%)
As of 08:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas